Global
Austria
Japan
Belgium
Brazil
Netherlands
Portugal
Czech Republic
Spain
Denmark
Sweden
France
Germany
Taiwan
Ireland
United Kingdom
Italy
We presented new results from the APOLLO Phase 3 study of patisiran, an investigational RNAi therapeutic for the treatment of hereditary ATTR (hATTR) amyloidosis, at the International Congress on Neuromuscular Diseases (ICNMD), held July 6-10, 2018 in Vienna, Austria. Obici et al. – “APOLLO Phase 3...
We presented additional results from the APOLLO Phase 3 study of patisiran, an investigational RNAi therapeutic for the treatment of hereditary ATTR (hATTR) amyloidosis, at the 4th Congress of the European Academy of Neurology (EAN), held June 16-19, 2018 in Lisbon, Portugal. Coelho et al. –...